Menu
Search
|

Menu

Close
X

Ipsen SA IPN.PA (Paris Stock Exchange)

119.55 EUR
-2.35 (-1.93%)
As of Mar 22
chart
Previous Close 121.90
Open 122.50
Volume 95,244
3m Avg Volume 106,233
Today’s High 122.95
Today’s Low 119.55
52 Week High 155.95
52 Week Low 107.50
Shares Outstanding (mil) 83.81
Market Capitalization (mil) 10,019.34
Forward P/E 25.68
Dividend (Yield %) 1.00 ( 0.84 )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 13 analysts

KEY STATS

Revenue (mm, EUR)
FY18
1,125
FY17
2,012
FY16
1,671
EPS (EUR)
FY18
2.379
FY17
3.256
FY16
2.730
*Note: Units in Millions of Euro
**Note: Units in Euro

KEY RATIOS

Price to Earnings (TTM)
vs sector
25.68
58.10
Price to Sales (TTM)
vs sector
4.27
8.84
Price to Book (MRQ)
vs sector
5.37
4.60
Price to Cash Flow (TTM)
vs sector
18.96
40.07
Total Debt to Equity (MRQ)
vs sector
32.80
17.66
LT Debt to Equity (MRQ)
vs sector
20.97
13.97
Return on Investment (TTM)
vs sector
17.02
12.12
Return on Equity (TTM)
vs sector
23.02
13.24

EXECUTIVE LEADERSHIP

Marc de Garidel
Non-Executive Chairman, Since 2016
Salary: €800,000.00
Bonus: €1,990,910.00
David Meek
Chief Executive Officer, Director, Since 2017
Salary: €900,000.00
Bonus: €438,840.00
Antoine Flochel
Vice Chairman of the Board, Since 2005
Salary: --
Bonus: --
Aymeric le Chatelier
Chief Financial Officer, Executive Vice President, Since 2016
Salary: --
Bonus: --
Regis Mulot
Chief Human Resource Officer, Executive Vice President, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

65, quai Georges Gorse
BOULOGNE-BILLANCOURT     92100

Phone: +331.58335000

Ipsen SA is a France-based biopharmaceutical group specialized in specialty care. The Company operates globally through two segments: Specialty Care and Consumer Healthcare. In Specialty Care, the Company is focused on various therapeutic areas, including oncology, neurosciences and rare diseases. Its oncology portfolio includes Somatuline, Decapeptyl, Cabometyx and Onivyde. Its neuroscience portfolio includes Dysport, and in rare diseases key products are NutropinAq and Increlex. Its primary care portfolio includes Smecta, Forlax, Fortrans, Eziclen, and Tanakan. In oncology Ipsen focuses on a number of disease areas, which include neuroendocrine tumors, renal cell carcinoma, hepatocellular carcinoma and pancreatic cancer. In addition, the Company has specialism in neurotoxin research and operates three research and development centers located in France, the United Kingdom and the United States.

SPONSORED STORIES